Across our pipeline we have announced an unprecedented 16 positive Phase III trials this year, with four since our previous results including high-impact readouts for baxdrostat in hypertension and ...
Emkay Research has reaffirmed their BUY recommendation on Indus Towers, upgrading the target price to Rs460 from Rs410, a 12% increase, reflecting strong quarterly results and improved client ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback